• HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Auteur:Di Leo, Angelo; Larsimont, Denis; Gancberg, David; Järvinen, Tero; Beauduin, Marc; Vindevoghel, Anita; Michel, Jeffrey; Focan, Christian; Ries, Fernand; Gobert, P H; Closon-Dejardin, Marie Thérèse; Dolci, Stella; Rouas, Ghizlane; Paesmans, Marianne; Lobelle, Jean Pierre; Isola, Jorma; Piccart-Gebhart, Martine
Informations sur la publication:Annals of oncology, 12, 8, page (1081-1089)
Statut de publication:Publié, 2001-08
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- surgery
Chemotherapy, Adjuvant
Confidence Intervals
Cyclophosphamide -- administration & dosage
DNA Topoisomerases, Type II, Eukaryotic -- analysis
DNA-Binding Proteins
Epirubicin -- administration & dosage
Fluorouracil -- administration & dosage
Genes, erbB-2 -- genetics
Methotrexate -- administration & dosage
Middle Aged
Predictive Value of Tests
Receptor, erbB-2 -- analysis
Retrospective Studies
Treatment Outcome
Tumor Markers, Biological -- analysis
Note générale:Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't